Eledon Pharmaceuticals, Inc. Retained Earnings
Eledon Pharmaceuticals, Inc. (ELDN) had Retained Earnings of -$471.86 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$471.86M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$440.23M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$401.20M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$390.76M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$471.86M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$440.23M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$401.20M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$390.76M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$373.30M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$362.08M 10-Q/A · filed 2025-08-14 | |
| 2024-12-31 | -$355.59M 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$310.97M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$387.94M 10-Q · filed 2024-08-19 | |
| 2024-03-31 | -$343.03M 10-Q/A · filed 2024-08-19 | -$253.49M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$319.40M 10-K/A · filed 2025-08-14 | -$243.19M 10-K · filed 2024-03-28 |
| 2023-09-30 | -$289.30M 10-Q · filed 2024-11-12 | -$233.56M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$279.40M 10-K/A · filed 2024-08-19 | -$223.22M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$213.64M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$202.87M 10-K/A · filed 2024-08-19 | |
| 2022-09-30 | -$144.48M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$134.01M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$124.76M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$114.90M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$106.09M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$96.28M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$88.89M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$80.39M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$74.49M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$68.34M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | -$65.76M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$57.58M 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$53.44M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$50.55M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | -$46.45M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$41.57M 10-K · filed 2020-03-17 | |
| 2018-09-30 | -$37.00M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$33.50M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | -$30.31M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | -$27.51M 10-K · filed 2019-03-28 | |
| 2017-09-30 | -$25.40M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$22.43M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$173.26M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | -$14.39M 10-K · filed 2018-04-02 | -$169.40M 10-K · filed 2017-03-03 |
| 2016-09-30 | -$165.66M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$156.39M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$142.86M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$131.44M 10-K · filed 2017-03-03 | |
| 2015-09-30 | -$120.42M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | -$108.57M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | -$99.61M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | -$86.35M 10-K · filed 2016-03-10 | |
| 2014-09-30 | -$80.14M 10-Q · filed 2014-11-13 | |
| 2013-12-31 | -$63.05M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |